Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma

Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma

BackgroundThe clinical consequences of pancreatic exocrine insufficiency and its treatment in advanced pancreatic ductal adenocarcinoma (PDAC) are poorly investigated. This retrospective study aims at investigating the pancreatic enzyme replacement therapy (PERT) use and its impact on survival and m...

Full description

Bibliographic Details
Main Authors: Ilaria Trestini, Luisa Carbognin, Umberto Peretti, Isabella Sperduti, Alberto Caldart, Daniela Tregnago, Alice Avancini, Alessandra Auriemma, Giulia Orsi, Sara Pilotto, Luca Frulloni, Gabriele Capurso, Emilio Bria, Michele Reni, Giampaolo Tortora, Michele Milella
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
pancreatic enzyme replacement therapy
advanced pancreatic adenocarcinoma
survival
maldigestion
weight gain
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.688889/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.688889/full

Similar Items